Peiminine

CAS No. 18059-10-4

Peiminine( Verticinone | Raddeanine )

Catalog No. M18142 CAS No. 18059-10-4

Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 64 In Stock
10MG 100 In Stock
25MG 167 In Stock
50MG 248 In Stock
100MG 374 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Peiminine
  • Note
    Research use only, not for human use.
  • Brief Description
    Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
  • Description
    Peiminine is an effective inhibitor for lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury.
  • In Vitro
    Cell Cytotoxicity Assay Cell Line:HepG2, Hela, SW480, MCF-7 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL, 10 μg/mL, 12μg/mL, and 14 μg/mL Incubation Time:24 h, 48 h, 72 h Result:Exhibited a significant inhibition on the survival of HepG2, Hela, SW480 and MCF-7 cells with the IC50 values were 4.58, 4.89, 5.07 and 5.12 μg/mL at 24 h, respectively.Apoptosis Analysis Cell Line:HepG2 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL, 8 μg/mL Incubation Time:24 h Result:Dissociated chromosome to produce DNA fragments dose-dependently.Cell Cycle Analysis Cell Line:HepG2 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL Incubation Time:24 h Result:Decreased the percentage of G1 phases from 65.15% ± 0.78 to 49.55% ± 0.17 with the increase of concentrations. Increased the percentage of G2/M phases from 17.32% ± 0.20 to 39.99% ± 0.47 with the increase of concentrations.Western Blot Analysis Cell Line:HepG2 Concentration:2 μg/mL, 4 μg/mL, 6 μg/mL Incubation Time:24 h Result:Reduced the expression of procaspase-3, PARP1, procaspases-8 and -9, and Bcl-2 at 2-6 μg/mL.
  • In Vivo
    Animal Model:ulcerative colitis model Dosage:3mg/kg Administration:Intraperitoneal injection (i.p.)Result:Reduced inflammation, mucosal ulcers, involvement of digestive system layers, and infltration of inflammatory cells.Reduced the levels of MPO and NO generated in the rectal tissue.Reduced cell proliferation in spleen cell.Decreased the production of f IL-1β, IL-6, and TNF-α cytokines.Reduced expression levels of genes IL-1β, IL-6, TNF-α, iNOS, and COX2.Animal Model:Ovariectomized (OVX) rat model Dosage:10 mg/kg Administration:Intraperitoneal injection (i.p.)Result:Alleviated the bone loss caused by surgical castration.Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.Animal Model:Allergic dermatitis model Dosage:1 mg/kg, 5 mg/kg Administration:were applied to the dorsal skin Result:Alleviated the bone loss caused by surgical castration.Improved the expression of COL1A1 and β-catenin and reduced the increase expression of PPAR-γ in trabecular bone.
  • Synonyms
    Verticinone | Raddeanine
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    Others
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    18059-10-4
  • Formula Weight
    429.64
  • Molecular Formula
    C27H43NO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL; 232.75 mM
  • SMILES
    CC1CCC2C(C3CCC4C(C3CN2C1)CC5C4CC(=O)C6C5(CCC(C6)O)C)(C)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Neratinib

    A potent, highly selective, irreversible HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays.

  • Epimedin B

    Epimedin B has potential activity against osteoporosis by stimulating osteoblasts.

  • AZD-9291 dimesylate

    A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.